RX Note

JULY 15, 2023

Introduction Atopic dermatitis (eczema) is a chronic, pruritic, inflammatory skin disease that occurs most frequently in children but also affects many adults. Topical Treatments Topical anti-inflammatory therapy with topical corticosteroids (first-line treatment) or topical calcineurin inhibitors (e.g.

52

52

European Pharmaceutical Review

JANUARY 31, 2023

EoE is a chronic, progressive inflammatory disease that damages the oesophagus and prevents it from working properly. Across Part A and Part B , of which the approval was based on, 74 percent of patients were previously treated with swallowed topical corticosteroids.

93

93

RX Note

JULY 15, 2023

Introduction Topical corticosteroids have a major role in the management of many skin diseases. The potency classification of topical corticosteroid above is extracted from Australian Medicines Handbook , which potency estimate is based on vasoconstrictive ability, inhibition and potential for causing adverse effects.

Diabetes 52

Diabetes 52

Express Pharma

JANUARY 11, 2024

billion in 2032, in line with the steadily increasing disease prevalence and the entrance of novel agents, according to GlobalData. These therapies are likely to adopted for patients with chronic gout or with hyperuricemia that is likely to lead to gout in the long-term. per cent from $4.6 billion in 2022 to $10.8

Biosimilars 93

Biosimilars Compounding 93

PharmD Live

JUNE 13, 2022

Because of the insidious nature of chronic kidney disease, and because most people affected do not have symptoms until the condition becomes advanced, it is sometimes under-recognized by busy healthcare providers. According to the National Kidney Foundation, kidney disease affects an estimated 37 million people in the United States.

Diabetes 52

Diabetes Physician Offices Hospitals 52

pharmaphorum

JULY 19, 2022

The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. million people in the US.

Labelling 98

Labelling 98

Pharma Marketing Network

DECEMBER 6, 2021

NEW YORK, December 6 th , 2021 (PRNEWSWIRE) – Tap Native, the leading health-focused content discovery platform, today unveiled a list of the top 20 most popular health topics viewed by consumer audiences in 2021. million unique URLs across the top 100 largest health websites in its network to determine which topics were viewed most.

Diabetes 52

Diabetes Immunity Immunization Vaccines 52

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. Ochre Bio will also expand its platforms for drug discovery and development that include a new RNA chemistry and an exploratory platform for expanding its research to more liver diseases.

52

52

Fusion Pharmacy

APRIL 29, 2022

It is estimated that more than 50 million Americans are currently suffering from chronic pain due to a traumatic injury, a degenerative disease, a congenital condition, or simply from years of poor posture. Typically, pain medication is prescribed as the first line of treatment for chronic pain.

Compounding 52

Compounding Specialty Pharmacies Dosage 52

pharmaphorum

OCTOBER 22, 2021

Sanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin disease. The post Dupixent scores a first in rare skin disease prurigo nodularis appeared first on.

Immunity 105

Immunity Immunization 105

pharmaphorum

MAY 31, 2022

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN). The post FDA grants speedy review to Dupixent rare skin disease appeared first on.

116

116

ALiEM - Pharm Pearls

DECEMBER 4, 2023

The patient was recently admitted to the hospital eight days prior to presentation for purulent urethral discharge where he received a course of topical antibiotics and was discharged. Penile Calciphylaxis in a Patient with End-stage Renal Disease: A Case Report and Review of the Literature. Am J Kidney Dis. 2015 Jul;66(1):133-46.

Hospitals 148

Hospitals Medical Schools Diabetes 148

pharmaphorum

SEPTEMBER 29, 2022

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease following a priority review. Here is a patient (*written consent obtained) I saw just 2 weeks ago with severe disease. — Brian S.

Immunity 69

Immunity Immunization Vaccines 69

RX Note

JANUARY 4, 2024

For 2023/2024 edition, it covers a total of 71 common health topics. Minor Illness or Major Disease, 2016 Minor Illness or Major Disease discusses in detail the diagnosis and management of frequently encountered ailments in community pharmacy practice. It is updated annually. A problem-based learning approach with cases studies.

Community Pharmacies 52

Community Pharmacies Patient Counseling 52

LifeProNow

MARCH 28, 2023

Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that impacts approximately 14 million people in Europe. Current therapies include topicals, orals and biologics. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. compared to 0.5% in the placebo group.

Adverse Reactions 130

Adverse Reactions Immunity Immunization Labelling 130

pharmaphorum

DECEMBER 18, 2020

Integrating personal experiences and patient-reported data, Health Union recently hosted a one-day virtual event entitled The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experience , featuring real-time conversations between people living with chronic conditions and industry experts. How can pharma keep up?

59

59

pharmaphorum

SEPTEMBER 28, 2020

The DHCoE has a network of experts that are available for FDA staff to consult with on topics such as artificial intelligence, wearables, digital therapeutics , real-world evidence, and cybersecurity. Its remit will be to support and encourage developers, including newcomers to healthcare, to translate new technology into usable products.

144

144

Digital Pharmacist

MARCH 26, 2024

This realization has led to an increasing interest in alternative approaches like functional medicine, which aims to uncover and treat the root causes of chronic health issues rather than continuing to manage symptoms. According to the CDC , six in ten adults in the US have a chronic disease and four in ten adults have two or more.

Immunity 52

Immunity Immunization Pharmacy Management 52

European Pharmaceutical Review

FEBRUARY 24, 2023

About ruxolitinib cream Ruxolitinib cream is a novel cream formulation of Incyte’s selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib, approved by the US Food & Drug Administration (FDA) for topical treatment of nonsegmental vitiligo in patients 12 years of age and older. What led to recommendation of the JAK inhibitor?

102

102

Safe Biologics

NOVEMBER 12, 2023

On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer.

Biosimilars 113

Biosimilars 113

Putting Patients First Blog

FEBRUARY 5, 2024

A Reminder of NHC Benefits February 5, 2024 By: Bob Scott, Director, Member Services The National Health Council (NHC) brings diverse organizations together to forge consensus, drive patient-centered health policy, and provide a united voice for the more than 160 million people with chronic diseases and disabilities and their family caregivers.

Documentation 59

Documentation Communication 59

pharmaphorum

JULY 19, 2021

The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light therapy. Download the PDF here.

Diabetes 59

Diabetes 59

Quality Matters

JUNE 12, 2023

Examples of complex generics include enoxaparin injection, orlistat lipase inhibitor, acyclovir topical cream, and epinephrine auto-injector. For patients with multiple chronic illnesses that require monthly drug refills, the availability of generics may make the difference between being able to afford or stopping treatment.

Generic Medicine 52

Generic Medicine Dosage Prescription Filling Diabetes 52

Pharmaceutical Technology

AUGUST 11, 2022

GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory bowel disease (IBD) patients. IBD is a fatal, chronic inflammation of the gastrointestinal tract. Topic sponsors are not involved in the creation of editorial content.

Immunity 52

Immunity Immunization 52

Putting Patients First Blog

FEBRUARY 29, 2024

In its 32-year history, the CDMRP has funded research into a plethora health care issues that impact the chronic illness community including breast cancer, chronic pain management, epilepsy, melanoma, multiple sclerosis, etc. In FY2023, over 30 health conditions were examined within CDMRP.

52

52

RX Note

JANUARY 11, 2024

Historically, dry eye disease (DED) has been classified into 2 general groups: Aqueous deficient DED Decreased tear production due to Sjogren's syndrome, older age and diabetes mellitus. The lipids, or oily component, surround the tear film and help to prevent evaporation of the water.

Diabetes 52

Diabetes Dosage Chemotherapy Community Pharmacies 52

PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

Diabetes 40

Diabetes Biosimilars 40

Board Vitals - Pharmacist

NOVEMBER 28, 2022

While many anesthesiologists work in a surgical setting, some choose to specialize in the treatment and management of chronic pain. In these cases, anesthesiologists work with patients suffering from migraines or other chronic conditions. The following topics are on the USMLE Step 1 : . Advanced Topics in Anesthesiology 50%.

Medical Schools 98

Medical Schools Communication Immunity Immunization 98

Pharmaceutical Technology

MARCH 21, 2023

It has also received regulatory approvals in many countries to treat chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, eosinophilic esophagitis (EoE) or prurigo nodularis in different age groups. The fully human monoclonal antibody Dupixent blocks the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways signalling.

52

52

pharmaphorum

JANUARY 19, 2023

It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Pharma and healthcare together can tackle chronic diseases.

Hospitals 96

Hospitals Vaccines 96

pharmaphorum

NOVEMBER 1, 2022

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more.

Clinical Pharmacology 52

Clinical Pharmacology 52

Pharmaceutical Technology

NOVEMBER 17, 2022

Despite affecting nearly one in ten women in the UK alone, endometriosis still lacks proper research, funding, and disease awareness among both the medical community and the public. As a result, women wait eight years on average for a diagnosis after initial symptom onset, a figure that has not changed in a decade.

102

102

pharmaphorum

DECEMBER 15, 2021

If approved, Opzelura would provide an alternative to steroid drugs currently used to treat vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US. 52-week data is expected in the coming weeks. billion in this indication alone.

111

111

pharmaphorum

MAY 18, 2021

Ruxolitinib is a topical Janus kinase (JAK) inhibitor that could provide an alternative to the steroids commonly used to treat these skin conditions, although these drugs have some undesirable side-effects. Over-activity of the JAK signalling pathway has been shown to drive the inflammation that causes vitiligo and drives its progression.

Immunity 52

Immunity Immunization 52

Putting Patients First Blog

MARCH 27, 2023

Specifically, we encourage you to hold such a forum during the first half of the year to seek input and hear concerns from national organizations that represent beneficiaries, particularly those with serious, life-threatening, chronic, and/or disabling conditions, as well as groups active in advocating for healthcare consumer affordability.

Diabetes 40

Diabetes 40

pharmaphorum

DECEMBER 29, 2021

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can’t control symptoms using topical prescription therapies. It continues to grow strongly with Sanofi reporting a 53% rise in sales to more than $4.1

Labelling 111

Labelling 111

Safe Biologics

JANUARY 12, 2024

Chronic illnesses such as arthritis, Crohn’s disease, psoriasis, and various forms of cancer often require treatment plans tailored over years of trial and error with different products before a patient’s disease or condition is stabilized. Read ASBM’s statement on the announcement here.

Biosimilars 130

Biosimilars Drug Pricing 130